SCHEMBL13675776

SCHEMBL13675776

Cc1cccc(NC(=O)/C=C/c2ccc(C(C)(C)C)cc2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 4/20 0.74
MMP2 P08253 4/20 0.74
MMP9 P14780 4/20 0.74
TRPV1 Q8NER1 10/20 0.73
MAOB P27338 3/20 0.73
EGFR P00533 1/20 0.73
MAOA P21397 1/20 0.73
RAB9A P51151 3/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
NPC1 O15118 2/20 0.64
MAPT P10636 2/20 0.62
MAPK1 P28482 2/20 0.62
LMNA P02545 2/20 0.62
KDM4E B2RXH2 1/20 0.62
POLB P06746 1/20 0.62
HPGD P15428 1/20 0.62
SMN1; SMN2 Q16637 2/20 0.60
TSHR P16473 1/20 0.60
MTOR P42345 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13675778 0.88 TRPV1 (0.70) MMP1MMP2MMP9TRPV1RAB9A
SCHEMBL3997459 0.87 MMP1 (0.75) MMP1MMP2MMP9TRPV1MAOB
SCHEMBL3997455 0.87 MMP1 (0.75) MMP1MMP2MMP9TRPV1MAOB
SCHEMBL13675636 0.86 TRPV1 (0.71) MMP1MMP2MMP9TRPV1MAOB
SCHEMBL13675780 0.86 MAOB (0.72) MMP1MMP2MMP9TRPV1MAOB
N-M-Tolylcinnamamide SCHEMBL3732518 0.85 MMP1 (1.00) MMP1MMP2MMP9MAOBEGFR
SCHEMBL4006434 0.85 TRPV1 (1.00) MMP1MMP2MMP9TRPV1MAOB
N-M-Tolylcinnamamide SCHEMBL1601210 0.85 MMP1 (1.00) MMP1MMP2MMP9MAOBEGFR
SCHEMBL4006429 0.85 TRPV1 (1.00) MMP1MMP2MMP9TRPV1MAOB
N-M-Tolylcinnamamide SCHEMBL3732520 0.85 MMP1 (1.00) MMP1MMP2MMP9MAOBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. 2009-10-22 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7582657-B2 Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex AMGEN INC. (US) 2009-09-01 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
US-7579347-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2009-08-25 US disclosed
EP-1780196-A2 Pyridine derivatives for use as vanilloid receptor ligands Amgen, Inc (US) 2007-05-02 EP disclosed
EP-1764358-A2 Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain Amgen, Inc (US) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264424-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS TRPV1, TRPV2, TRPV3 MMP1 1052/4885MMP2 1236/4885MMP9 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.